Browsing: Science

For decades, researchers have debated how often overdiagnosis actually occurs. Estimates from randomized trials have differed sharply, with some studies suggesting that 30-50% of breast cancers detected through screening could fall into this category. Those figures have influenced international discussions about both the benefits and possible harms of population-based breast cancer screening.

For decades, researchers have debated how often overdiagnosis actually occurs. Estimates from randomized trials have differed sharply, with some studies suggesting that 30-50% of breast cancers detected through screening could fall into this category. Those figures have influenced international discussions about both the benefits and possible harms of population-based breast cancer screening.

For decades, researchers have debated how often overdiagnosis actually occurs. Estimates from randomized trials have differed sharply, with some studies suggesting that 30-50% of breast cancers detected through screening could fall into this category. Those figures have influenced international discussions about both the benefits and possible harms of population-based breast cancer screening.

For decades, researchers have debated how often overdiagnosis actually occurs. Estimates from randomized trials have differed sharply, with some studies suggesting that 30-50% of breast cancers detected through screening could fall into this category. Those figures have influenced international discussions about both the benefits and possible harms of population-based breast cancer screening.

Phelan-McDermid syndrome is a rare genetic disorder caused by a deletion or mutation involving the SHANK3 gene on chromosome 22. It can lead to a broad range of medical, intellectual, and behavioral challenges. Most people with the syndrome also meet the criteria for autism spectrum disorder, and changes affecting SHANK3 are believed to account for as many as one percent of autism spectrum disorder cases.